9,425 Shares in Abbott Laboratories $ABT Bought by EJMK Ventures LLC

EJMK Ventures LLC bought a new stake in Abbott Laboratories (NYSE:ABT) during the 4th quarter, HoldingsChannel reports. The firm bought 9,425 shares of the healthcare product maker’s stock, valued at approximately $1,181,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tulsa Wealth Advisors INC bought a new stake in Abbott Laboratories in the fourth quarter worth approximately $225,000. Integrated Investment Consultants LLC boosted its stake in Abbott Laboratories by 44.9% during the fourth quarter. Integrated Investment Consultants LLC now owns 18,732 shares of the healthcare product maker’s stock worth $2,347,000 after acquiring an additional 5,803 shares in the last quarter. Bank of Hawaii grew its holdings in Abbott Laboratories by 1.1% in the fourth quarter. Bank of Hawaii now owns 26,172 shares of the healthcare product maker’s stock worth $3,279,000 after purchasing an additional 283 shares during the period. Reflection Asset Management bought a new stake in Abbott Laboratories in the fourth quarter valued at $227,000. Finally, CFO Capital Management LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at about $1,517,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.1%

NYSE:ABT opened at $88.48 on Friday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm’s 50 day moving average is $90.08 and its 200 day moving average is $106.60. The stock has a market capitalization of $154.12 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period last year, the business posted $1.09 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. Abbott Laboratories’s payout ratio is presently 70.59%.

Analyst Ratings Changes

ABT has been the topic of a number of research reports. The Goldman Sachs Group lowered their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Weiss Ratings downgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday. Wells Fargo & Company reduced their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Royal Bank Of Canada lowered their price target on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $118.30.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.